ASE – Real vaqt narxi. Valyuta: USD
8.37
-0.98 (-10.48%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
8.21
-0.16 (-1.91%)
Bozordan keyin: Mar 27, 2026, 6:27 PM EDT
Armata Pharmaceuticals, Inc. global miqyosida antibiotiklarga chidamli infeksiyalar uchun maqsadli bakteriofag terapiyasini ishlab chiqishga qaratilgan klinik bosqichdagi biotexnologiya kompaniyasi hisoblanadi. Kompaniya o'z mahsulotlarini o'ziga xos bakteriofag asosidagi texnologiyasidan foydalangan holda ishlab chiqadi. Kompaniyaning mahsulot nomzodlari orasida Staphylococcus aureus bakteriemiyasini davolash uchun AP-SA02; Pseudomonas aeruginosa uchun AP-PA02; va pnevmoniyani davolash uchun AP-PA03 mavjud. Kompaniya Merck Sharp & Dohme Corp. bilan aniqlanmagan yuqumli kasallik qo'zg'atuvchilariga qarshi kurashish uchun sintetik bakteriofag nomzodlarini ishlab chiqish bo'yicha ilmiy-tadqiqot hamkorlik shartnomasiga ega. Kompaniya Los-Anjeles, Kaliforniyada joylashgan. Armata Pharmaceuticals, Inc. Innoviva, Inc. kompaniyasining sho'ba korxonasi hisoblanadi.
| Ism | Lavozim |
|---|---|
| Dr. Deborah L. Birx M.D. | CEO & Director |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
| Mr. David D. House | Senior VP of Finance & Principal Financial Officer |
| Mr. Peter Hubbard | Vice President of Operations |
| Ms. Bani Tchekanova Ph.D. | Head of Regulatory Strategy & Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-26 | 8-K | tm263967d1_8k.htm |
| 2026-01-13 | 8-K | tm262898d1_8k.htm |
| 2025-12-01 | 8-K | tm2532031d2_8k.htm |
| 2025-11-12 | 10-Q | armp-20250930x10q.htm |
| 2025-10-22 | 8-K | tm2529060d1_8k.htm |
| 2025-09-11 | 8-K | tm2525814d1_8k.htm |
| 2025-08-13 | S-3 | tm2523066d1_s3.htm |
| 2025-08-12 | 10-Q | armp-20250630x10q.htm |
| 2025-06-13 | 8-K | tm2517977d1_8k.htm |
| 2025-05-19 | 8-K | tm2515395d1_8k.htm |